Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...
From axolotls to zebrafish, stem cells possess remarkable regenerative abilities, enabling them to restore lost limbs and repair damaged organs. These extraordinary capabilities, however, are not ...
Pluristyx Inc., the leader in advanced induced pluripotent stem cell (iPSC) technologies, announces today the Initial Close of their Series A financing led by a global Fortune 500 company along with ...
Preclinical study showed iRECs Integrated into host vascular network and revascularized the ischemic eye, rescuing the tissue.
Biomedical engineers use iPSCs to grow specialized retinal endothelial cells, successfully regenerating damaged eye blood ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), ...
Southwest Research Institute (SwRI) has demonstrated a new application for its cell-expansion bioreactor to advance tissue engineering and cell-based therapies for treatment of injuries and diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results